Filing Flows › Prelude Therapeutics (PRLD) › Q2 2026 › vs Q1 2026
Prelude Therapeutics (PRLD) Q2 2026 vs Q1 2026 (quarter over quarter)
Prelude Therapeutics's revenue rose $1.1M (+25%) from $4.6M in Q1 2026 to $5.7M in Q2 2026.
Prelude Therapeutics, Q2 2026: revenue $5.7M, operating margin -270.9%, net loss $13.9M, operating cash flow −$15.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $5.7M | $4.6M | $1.1M | +25% |
| Other income, net | $1.5M | $3.8M | −$2.3M | -60% |
| Net loss | $13.9M | $10.4M | $3.5M | +34% |
| Costs & expenses | $21.2M | $18.8M | $2.4M | +13% |
| Operating costs | $21.2M | $18.8M | $2.4M | +13% |
| Research & development | $16.1M | $13.6M | $2.5M | +19% |
| General & admin | $5.0M | $5.2M | −$129K | -3% |
| Operating cash sources | $18.0M | $24.1M | −$6.1M | -25% |
| Depreciation & amortization | $353K | $391K | −$38K | -10% |
| Share-based compensation | $2.0M | $2.0M | $27K | +1% |
| Cash used in operations | $15.6M | $21.7M | −$6.1M | -28% |
| Net loss absorbed | $13.9M | $10.4M | $3.5M | +34% |
| Working capital & other | $4.0M | $13.7M | −$9.7M | -71% |
Questions
How much did Prelude Therapeutics's revenue grow quarter over quarter in Q2 2026?
Prelude Therapeutics's revenue rose $1.1M (+25%) from $4.6M in Q1 2026 to $5.7M in Q2 2026.